Literature DB >> 3735114

Glare and contrast: indications for cataract surgery.

N S Jaffe.   

Abstract

The present method of using Snellen visual acuity to evaluate the vision of cataract patients is inadequate because it may grossly overestimate the nature of their visual world. Many of these patients have poor visual functioning as a result of glare disability and loss of contrast. The loss of visual contrast on the retina may be quantified using devices currently available and applicable to a clinical setting in the office. These are described. A study of glare disability in pseudophakic eyes following phacoemulsification or planned extracapsular cataract extraction with intact capsules is made and compared with a previous report of eyes with a primary posterior capsulotomy. It is recommended that glare disability be measured in eyes of cataract patients and be used as an indication for cataract surgery.

Entities:  

Mesh:

Year:  1986        PMID: 3735114     DOI: 10.1016/s0886-3350(86)80098-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  Comparison of contrast sensitivity between posterior chamber lenses of silicone and PMMA material.

Authors:  C Skorpik; I Gottlob; H Weghaupt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

2.  Glare sensitivity in early cataracts.

Authors:  M S Lasa; M J Podgor; M B Datiles; R C Caruso; B V Magno
Journal:  Br J Ophthalmol       Date:  1993-08       Impact factor: 4.638

3.  Cataracts among adults aged 30 to 49 years: a 10-year study from 1995 to 2004 in Korea.

Authors:  Hyun Kyung Cho; Kyung Sun Na; Eun Jung Jun; Sung Kun Chung
Journal:  Korean J Ophthalmol       Date:  2013-09-10

4.  Effect of cataract type and severity on visual acuity and contrast sensitivity.

Authors:  Javad Heravian Shandiz; Akbar Derakhshan; Ameneh Daneshyar; Abbas Azimi; Hadi Ostadi Moghaddam; Abbas Ali Yekta; Seyed Hosein Hoseini Yazdi; Habibollah Esmaily
Journal:  J Ophthalmic Vis Res       Date:  2011-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.